NCT00825266

Insulin Resistance in Pulmonary Arterial Hypertension

The Effect of Bosentan and Pioglitazone on Insulin Resistance in Pulmonary Arterial Hypertension

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate 1) the incidence of insulin resistance (a pre-diabetic state) in patients with pulmonary hypertension, and 2) test the utility of a validated PH therapy (Tracleer) versus Pioglitazone in the treatment of those patients found to have insulin resistance.

Detailed description

The Effect of Bosentan and Pioglitazone on Insulin Resistance in Pulmonary Arterial Hypertension ,is a study evaluating the incidence of insulin resistance in patients with pulmonary hypertension and testing the utility of a validated PH therapy(Tracleer) versus Pioglitazone in the treatment of those patients found to have insulin resistance.Patients with PAH must be stable on therapy for at least 3 months are considered for enrollment in this study.With the exception of PAH, subjects must be free of major medical illnesses, including diabetes mellitus ,malignancy or significant hepatic or renal disease.

Conditions

• Hypertension, Pulmonary

Interventions

Type	Name	Description
DRUG	bosentan	Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.
DRUG	Pioglitazone	Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.

Timeline

• Start date: 2008-09-01
• Primary completion: 2010-05-01
• Completion: 2010-05-01
• First posted: 2009-01-21
• Last updated: 2017-03-31
• Results posted: 2017-03-31

Locations

1 site across 1 country: United States